N-(4-quinolyl)urea | 89736-50-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(4-quinolyl)urea
• 英文别名: N-Quinolin-4-ylurea；quinolin-4-ylurea
• CAS: 89736-50-5
• 化学式: C₁₀H₉N₃O
• 分子量: 187.201
• InChiKey: PLUYBDWTZPHJJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-羟基喹啉-4-甲酰胺 在 formamide 作用下， 以67%的产率得到N-(4-quinolyl)urea
  参考文献：
  名称：

  Eckstein, Zygmunt; Lipczynska-Kochany, Ewa; Leszczynska, Ewa, Liebigs Annalen der Chemie, 1984, # 2, p. 395 - 396

  摘要：

  DOI：

文献信息

• PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF
  申请人：Trauner Dirk

  公开号：US20090181454A1

  公开（公告）日：2009-07-16

  The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

  本发明提供了一种合成的谷氨酸受体功能调节剂，该调节剂是一种光敏感（光反应性）调节剂。本发明还提供了一种光调节的谷氨酸受体，其中包括与谷氨酸受体非共价结合的主体合成调节剂。还提供了包括主体光调节谷氨酸受体的细胞和膜。本发明还提供了使用光调节谷氨酸受体的调节谷氨酸受体功能的方法。本发明还提供了识别调节谷氨酸受体功能的药剂的方法。
• 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists
  申请人：Aissaoui Hamed

  公开号：US20050043535A1

  公开（公告）日：2005-02-24

  The invention relates to novel 1-pyridin-4-yl urea derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.

  本发明涉及新型1-吡啶-4-基脲衍生物及其相关化合物，以及它们作为制备药物组合物的活性成分的用途。本发明还涉及相关方面，包括制备化合物的过程，含有这些化合物中的一个或多个的制药组合物，尤其是它们作为神经荷尔蒙拮抗剂的用途。
• Piperazine-alkyl-ureido derivatives
  申请人：Aissaoui Hamed

  公开号：US20060211707A1

  公开（公告）日：2006-09-21

  The invention relates to novel piperazine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.

  本发明涉及新型哌嗪衍生物及相关化合物，以及它们作为制备药物组合物的活性成分的用途。本发明还涉及相关方面，包括制备化合物的过程、含有其中一种或多种化合物的制药组合物，尤其是它们作为神经荷尔蒙拮抗剂的用途。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。
• Treatment of glial tumors with glutamate antagonists
  申请人：——

  公开号：US20030050224A1

  公开（公告）日：2003-03-13

  The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective to treat the glial tumor.

  本发明涉及一种治疗受试者神经胶质瘤的方法，该方法包括提供谷氨酸拮抗剂或NMDA受体拮抗剂，并在有效治疗神经胶质瘤的条件下将谷氨酸拮抗剂或NMDA受体拮抗剂施用于患有脑或脊髓神经胶质瘤的受试者。